AU2019327572B2 - ENPP1 polypeptides and methods of using same - Google Patents

ENPP1 polypeptides and methods of using same

Info

Publication number
AU2019327572B2
AU2019327572B2 AU2019327572A AU2019327572A AU2019327572B2 AU 2019327572 B2 AU2019327572 B2 AU 2019327572B2 AU 2019327572 A AU2019327572 A AU 2019327572A AU 2019327572 A AU2019327572 A AU 2019327572A AU 2019327572 B2 AU2019327572 B2 AU 2019327572B2
Authority
AU
Australia
Prior art keywords
polypeptide
enpp1
subject
seq
fusion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2019327572A
Other languages
English (en)
Other versions
AU2019327572A1 (en
Inventor
Demetrios Braddock
Paul STABACH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of AU2019327572A1 publication Critical patent/AU2019327572A1/en
Application granted granted Critical
Publication of AU2019327572B2 publication Critical patent/AU2019327572B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y306/00—Hydrolases acting on acid anhydrides (3.6)
    • C12Y306/01—Hydrolases acting on acid anhydrides (3.6) in phosphorus-containing anhydrides (3.6.1)
    • C12Y306/01009—Nucleotide diphosphatase (3.6.1.9), i.e. nucleotide-pyrophosphatase

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2019327572A 2018-08-31 2019-08-31 ENPP1 polypeptides and methods of using same Active AU2019327572B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862725607P 2018-08-31 2018-08-31
US62/725,607 2018-08-31
US201962830247P 2019-04-05 2019-04-05
US62/830,247 2019-04-05
PCT/US2019/049243 WO2020047520A1 (en) 2018-08-31 2019-08-31 Enpp1 polypeptides and methods of using same

Publications (2)

Publication Number Publication Date
AU2019327572A1 AU2019327572A1 (en) 2021-03-18
AU2019327572B2 true AU2019327572B2 (en) 2025-11-13

Family

ID=69643272

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019327572A Active AU2019327572B2 (en) 2018-08-31 2019-08-31 ENPP1 polypeptides and methods of using same

Country Status (7)

Country Link
US (2) US12344868B2 (https=)
EP (1) EP3844280A4 (https=)
JP (2) JP2021535153A (https=)
CN (2) CN120383683A (https=)
AU (1) AU2019327572B2 (https=)
CA (1) CA3110498A1 (https=)
WO (1) WO2020047520A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3126839A1 (en) * 2019-01-18 2020-07-23 Inozyme Pharma, Inc. Treatment of diseases involving deficiency of enpp1 or enpp3
KR20230047334A (ko) * 2020-05-27 2023-04-07 이노자임 파마, 인코포레이티드 혈관 평활근 세포 증식을 억제하기 위한 조성물 및 방법
WO2021252549A1 (en) * 2020-06-09 2021-12-16 Inozyme Pharma, Inc. Soluble enpp1 or enpp3 proteins and uses thereof
CA3246877A1 (en) * 2022-03-30 2023-10-05 Yale University METHOD AND COMPOSITIONS FOR THE TREATMENT, ALLEVIATION AND/OR PREVENTION OF DIFFUSE IDIOPATHIC SKELETAL HYPEROSTOSIS (DISH)
CN116769718A (zh) * 2023-04-21 2023-09-19 南京逸微健华生物科技有限公司 一种工程化细胞外囊泡及用途

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170340713A1 (en) * 2015-05-19 2017-11-30 Yale University Compositions for Treating Pathological Calcification Conditions, and Methods Using Same

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
WO1995019570A1 (en) 1994-01-14 1995-07-20 Genentech, Inc. Antagonists to insulin receptor tyrosine kinase inhibitor
US6043056A (en) 1998-11-06 2000-03-28 Incyte Pharmaceuticals, Inc. Cell surface glycoproteins
US6521645B2 (en) 2000-11-20 2003-02-18 The University Of Kansas Medical Center Methods for the treatment and prevention of urinary stone disease
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
US7888372B2 (en) 2001-03-23 2011-02-15 National Institutes Of Health (Nih) Compositions and methods for modulating bone mineral deposition
US20020183276A1 (en) 2001-03-23 2002-12-05 Burnham Institute Compositions and methods for modulating bone mineral deposition
US20030191073A1 (en) 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
AU2002324700A1 (en) 2001-08-14 2003-03-03 Bayer Ag Nucleic acid and amino acid sequences involved in pain
JP4200100B2 (ja) 2001-11-07 2008-12-24 アジェンシス，インコーポレイテッド 癌の処置および検出において有用な１６１ｐ２ｆ１０ｂと称される、核酸および対応タンパク質
WO2003072593A2 (en) 2002-02-21 2003-09-04 University Of Virginia Patent Foundation Bone targeting peptides
JP5199077B2 (ja) 2005-06-10 2013-05-15 アルタス ファーマシューティカルズ インコーポレイテッド シュウ酸オキシダーゼ結晶の投与による、シュウ酸塩濃度を低下させるための方法
WO2008105911A2 (en) 2006-08-02 2008-09-04 Altus Pharmaceuticals Inc. Crystallized oxalate decarboxylase and methods of use
US20080273206A1 (en) 2007-04-23 2008-11-06 University Of South Carolina Biomimetic Mineralization Method and System
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
GB0803352D0 (en) 2008-02-22 2008-04-02 Ntnu Technology Transfer As Oligopeptidic compounds and uses thereof
US8846603B2 (en) 2010-03-12 2014-09-30 Synageva Biopharma Corp. NPP1 fusion proteins
RU2601154C2 (ru) 2011-03-11 2016-10-27 Синаджива Байофарма Корп Гибридные белки npp1
WO2014126965A2 (en) 2013-02-13 2014-08-21 Yale University Compositions and methods for treating pathological calcification and ossification
EP2970940B1 (en) 2013-03-14 2018-07-25 Translate Bio, Inc. Mrna therapeutic compositions and use to treat diseases and disorders
ES2708565T3 (es) 2013-03-15 2019-04-10 Atyr Pharma Inc Conjugados de Fc-histidil-ARNt sintetasa
AU2014305843B2 (en) 2013-08-09 2019-08-29 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
EP3967755B1 (en) 2014-12-19 2024-03-27 Inozyme Pharma, Inc. Soluble npp1 for use in a method for treating pseudoxanthoma elasticum
EP3377105A4 (en) 2015-11-20 2019-04-24 Yale University COMPOSITIONS FOR THE TREATMENT OF ECTOPIC CALIBRATION DISORDERS AND METHODS THEREWITH
WO2017191274A2 (en) 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein
CA3032467A1 (en) 2016-08-05 2018-02-08 Yale University Compositions and methods for stroke prevention in pediatric sickle cell anemia patients
US20190367579A1 (en) * 2017-02-27 2019-12-05 Shattuck Labs, Inc. Tigit- and light-based chimeric proteins
AU2019267545A1 (en) 2018-05-08 2020-11-26 Yale University Compositions and methods for reducing progression of nephrolithiasis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170340713A1 (en) * 2015-05-19 2017-11-30 Yale University Compositions for Treating Pathological Calcification Conditions, and Methods Using Same

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Rath T, et al., (2013) 'Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics', Critical Reviews in Biotechnology, 35(2):235-254, doi:10.3109/07388551.2013.834293. *
Robbie GJ, et al., (2013) 'A Novel Investigational Fc-Modified Humanized Monoclonal Antibody, Motavizumab-YTE, Has an Extended Half-Life in Healthy Adults', Antimicrobial Agents and Chemotherapy, 57(12):6147-6153, doi:10.1128/aac.01285-13. *
Yin B, et al., (2015) 'Glycoengineering of Chinese hamster ovary cells for enhanced erythropoietin N-glycan branching and sialylation', Biotechnology and Bioengineering, 112(11):2343-2351, doi:10.1002/bit.25650. *

Also Published As

Publication number Publication date
CN120383683A (zh) 2025-07-29
JP2025000736A (ja) 2025-01-07
CN112930397A (zh) 2021-06-08
EP3844280A4 (en) 2022-09-14
CA3110498A1 (en) 2020-03-05
EP3844280A1 (en) 2021-07-07
WO2020047520A1 (en) 2020-03-05
US12344868B2 (en) 2025-07-01
US20220119782A1 (en) 2022-04-21
JP2021535153A (ja) 2021-12-16
CN112930397B (zh) 2025-05-09
US20260049294A1 (en) 2026-02-19
AU2019327572A1 (en) 2021-03-18

Similar Documents

Publication Publication Date Title
AU2019327572B2 (en) ENPP1 polypeptides and methods of using same
TWI706035B (zh) 利用醣苷內切酶突變體重塑醣蛋白及其使用方法
US9597378B2 (en) Blood coagulation factor VII and VIIa derivatives, conjugates and complexes comprising the same, and use thereof
CN103379915A (zh) Hsa相关组合物及使用方法
CA2997263C (en) Apoa-1 fusion polypeptides and related compositions and methods
US20240294889A1 (en) Dnase fusion polypeptides and related compositions and methods
US20250230423A1 (en) Enpp1 polypeptides and methods of using same
EP3493829B1 (en) Compositions and methods for stroke prevention in pediatric sickle cell anemia patients
RU2858269C2 (ru) Enpp1 полипептиды и способы их применения
HK40114509A (zh) 包含α-L-艾杜糖醛酸酶的融合蛋白和方法
WO2026028159A1 (en) Bifunctional degraders for the treatment of graves' disease
TW202542190A (zh) 包含酸性α—葡萄糖苷酶之融合蛋白及其方法
NZ738963B2 (en) Apoa-1 fusion polypeptides and related compositions and methods

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)